Belzutifan versus Everolimus for Advanced Renal-Cell Carcinoma. Reply

N Engl J Med. 2024 Nov 28;391(21):2062-2063. doi: 10.1056/NEJMc2411843.

Authors

Thomas Powles¹, Laurence Albiges², Brian Rini³

Affiliations

¹ Barts Cancer Centre, London, United Kingdom.
² Gustave Roussy, Villejuif, France.
³ Vanderbilt Ingram Cancer Center, Nashville, TN [email protected].

PMID: 39602645
DOI: 10.1056/NEJMc2411843

No abstract available

Publication types

Letter
Comment